---
title: "Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients"
id: "journal-of-the-american-heart-association-56-metabolic-and-safety-outcomes-of-statin-ezetimibe-versus-high-intensity-statin"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-56-metabolic-and-safety-outcomes-of-statin-ezetimibe-versus-high-intensity-statin"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Journal of the American Heart Association"
source_url: "https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.048711?ai=sg&mi=3&af=R"
published_at: "2026-07-03T10:24:17.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-56-metabolic-and-safety-outcomes-of-statin-ezetimibe-versus-high-intensity-statin
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Journal of the American Heart Association
- **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.048711?ai=sg&mi=3&af=R)
- **Published At:** 2026-07-03T10:24:17.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of the American Heart Association, Volume 15, Issue 13 , July 7, 2026. BackgroundHigh‐intensity statins are recommended for secondary prevention in atherosclerotic cardiovascular disease (ASCVD), but older adults frequently experience tolerability issues and adverse metabolic effects. Moderate‐intensity statin plus ezetimibe can achieve substantial low‐density lipoprotein cholesterol lowering, yet randomized data comparing metabolic and safety outcomes versus high‐intensity statins in older patients remain limited.MethodsThis subgroup analysis of the randomized SaveSAMS (Effects of High‐Dose Statin Versus Low‐Dose Statin Plus Ezetimibe on SAMS and on Reaching Target LDL‐Cholesterol Levels Among Older Patients With ASCVD) trial included patients aged ≥70 years with established ASCVD assigned to high‐intensity statin monotherapy (rosuvastatin 20 mg) or a moderate‐intensity statin plus ezetimibe (rosuvastatin 5 mg/ezetimibe 10 mg). Among 318 patients (monotherapy, n=168; combination, n=150), 6‐month changes in lipid parameters, metabolic biomarkers, and safety end points were compared.ResultsBoth strategies significantly improved lipid profiles. Combination therapy achieved greater non–high‐density lipoprotein cholesterol reduction (Δ −76.0 versus −66.0 mg/dL;P=0.047) and attenuated statin‐associated increases in lipoprotein(a) (Δ +0.1 versus +1.2 mg/dL;P=0.033).
## Clinical Analysis & Structured Key Points
Journal of the American Heart Association published a clinical update in Cardiology on 03 Jul 2026. The item focuses on Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients. Review the original article for the full source wording and details.
## Related Clinical Research

- [2026 ACC/AHA Dyslipidemia Guideline: Key implications for cholesterol and cardiovascular risk](https://medichelpline.com/clinical-feed/medical-news-today-0-is-your-cholesterol-too-high-per-the-new-acc-aha-guideline-5-things-to-know.md)
- [Clinicians’ Views on “Fighting the Ventilator”: Survey of ICU Practice and Gaps](https://medichelpline.com/clinical-feed/medrxiv-23-clinicians-perspectives-on-fighting-the-ventilator.md)
- [PBPK-guided Rosuvastatin Dose Adjustments with Ticagrelor by ABCG2 Genotype in Elderly](https://medichelpline.com/clinical-feed/medrxiv-19-pbpk-model-based-prediction-of-optimal-rosuvastatin-dosing-with-concomitant.md)
- [Psychosocial profile in adults with congenital heart disease by documented anxiety disorder history](https://medichelpline.com/clinical-feed/plos-one-21-psychosocial-profile-of-adults-with-congenital-heart-disease-according-to.md)
- [Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients](https://medichelpline.com/clinical-feed/circulation-5-laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.